Quick answer: Functional gastroenterology identifies and addresses the root biological causes of digestive dysfunction—including small intestinal bacterial overgrowth (SIBO, present in 60-80% of IBS patients on lactulose breath testing), intestinal permeability (“leaky gut”), H. pylori infection (affecting 44% of the global population), and the gut-brain axis dysregulation that connects gut symptoms to anxiety, depression, and neurological conditions. The low-FODMAP diet eliminates symptoms in 68-76% of IBS patients within 6 weeks (Staudacher 2011), while SIBO-specific antibiotic protocols (rifaximin) achieve 77% hydrogen SIBO eradication (Pimentel 2011 NEJM, n=1,260).
The Enteric Nervous System: The Second Brain
The enteric nervous system (ENS)—the 500 million neurons embedded in the gastrointestinal tract wall—operates largely independently of the central nervous system, earning the designation “the second brain” (Gershon 1998). The ENS controls the complex coordination of peristalsis, secretion, and absorption using the same neurotransmitters as the brain: serotonin (95% of body’s serotonin is produced in the gut, primarily by enterochromaffin cells), dopamine, acetylcholine, nitric oxide, neuropeptide Y, and substance P. The bidirectional gut-brain axis—comprising the vagus nerve (afferent fibers carrying gut signals to the brainstem), spinal afferents, hormonal signaling (GLP-1, PYY, ghrelin, CCK), and systemic immune/inflammatory signaling—means that gut dysfunction produces central nervous system effects (anxiety, depression, cognitive fog) while psychological stress directly alters gut motility, permeability, and microbiome composition.
Approximately 70% of the immune system resides in gut-associated lymphoid tissue (GALT)—including Peyer’s patches, mesenteric lymph nodes, and lamina propria immune cells. The intestinal epithelium serves as the boundary between the largest pool of foreign antigens (the 38 trillion bacteria and their metabolites in the gut lumen) and the systemic immune system. This boundary requires exquisite balance: adequate barrier function to prevent pathogen translocation, while maintaining selective permeability for nutrients and maintaining immune tolerance to commensal bacteria and food antigens. Disruption of this balance—through tight junction protein dysfunction, NSAID-mediated prostaglandin depletion, alcohol, stress-induced cortisol, or dysbiosis-driven inflammation—creates the intestinal permeability that allows lipopolysaccharide (LPS) and undigested food proteins into systemic circulation, initiating inflammatory cascades in distant organs.
SIBO: Small Intestinal Bacterial Overgrowth
Small intestinal bacterial overgrowth (SIBO)—defined as greater than 10³ CFU/mL bacteria in the upper small intestine, vs. the normal less than 10³ CFU/mL—represents one of the most common and frequently misdiagnosed conditions in functional gastroenterology. The small intestine’s normal relative sterility (compared to the colon’s 10¹² bacteria/mL) is maintained by migrating motor complex (MMC) activity (“the intestinal housekeeper”—phase III contractions occurring every 90-120 minutes during fasting, sweeping bacteria toward the colon), adequate gastric acid (preventing bacterial colonization from the mouth), ileocecal valve competence (preventing colonic bacterial reflux), and IgA secretion into the intestinal lumen.
SIBO develops when any of these defenses fail: proton pump inhibitor (PPI) use impairs gastric acid sterilization; diabetic gastroenteropathy and hypothyroidism impair MMC motility; post-infectious IBS (PI-IBS)—affecting 10-15% following acute gastroenteritis—damages the MMC via autoimmune attack on the interstitial cells of Cajal (ICC), the intestinal pacemaker cells; adhesions from prior surgery create stasis zones; and narcotic analgesics suppress all intestinal motility, predictably causing bacterial overgrowth. The clinical presentation is highly variable and mimics many other GI conditions: bloating (often severe and progressive through the day), abdominal pain or discomfort, altered bowel habits (diarrhea in hydrogen-dominant SIBO, constipation in methane-dominant SIBO/intestinal methanogen overgrowth), and nutrient malabsorption (fat malabsorption from bacterial bile acid deconjugation → steatorrhea; B12 deficiency from bacterial competitive uptake; iron deficiency from inflammation; fat-soluble vitamin deficiencies).
The gold standard for SIBO diagnosis is quantitative culture of jejunal aspirate—an invasive procedure rarely performed outside research settings. The clinically used alternative is breath testing: lactulose or glucose breath tests measuring hydrogen (H₂) and methane (CH₄) gas production. Bacterial fermentation of carbohydrates produces H₂ (primarily by Bacteroides, Escherichia, Clostridium); archaeal methanogenesis by Methanobrevibacter smithii converts H₂ to CH₄ (this methane dominance pattern is associated specifically with constipation—the Pimentel 2006 Am J Gastroenterol data found methane-producers twice as likely to have constipation and that CH₄ directly inhibits intestinal transit). The recently identified hydrogen sulfide SIBO (H₂S—produced by Fusobacterium, Desulfovibrio) presents with diarrhea and may show false-negative results on standard breath tests (H₂S is absorbed before expiration)—specialized tri-gas breath testing or FoodMarble H₂S device capture this pattern.
Treatment: Rifaximin (Xifaxan)—a non-absorbed antibiotic with minimal systemic bioavailability, active only within the GI lumen—is the most evidence-based SIBO antibiotic. The TARGET-1 and TARGET-2 trials (Pimentel 2011, NEJM, n=1,260 total, IBS-D) found rifaximin 550 mg TID × 14 days significantly superior to placebo for adequate relief (40.7% vs. 31.7%, p<0.001)—with sustained benefit through 12 weeks post-treatment. For methane/constipation-dominant SIBO, rifaximin combined with neomycin (500 mg BID × 10 days) or lovastatin achieves significantly higher eradication rates than rifaximin alone (Pimentel 2020 data). Elemental diet (amino acid-based, carbohydrate-limited formula providing inadequate substrate for bacterial fermentation while maintaining human nutrition) for 14 days achieves 80-84% SIBO eradication—comparable to antibiotic therapy—and is particularly valuable for patients with multiple antibiotic failures or severe chemical sensitivities. Herbal antimicrobials (berberine, oregano oil, allicin from garlic, neem) have two-week courses showing equivalent efficacy to rifaximin in a single comparative study (Chedid 2014 Global Advances in Health and Medicine).
SIBO recurrence prevention is equally critical: addressing the underlying motility disorder (prokinetics: low-dose naltrexone 0.5-2 mg/night for immune modulation and motility; ginger 1,000-2,000 mg as a natural prokinetic activating 5-HT4 receptors; prucalopride for severe motility disorders; iberogast—a multi-herb formulation with the highest prokinetic evidence in European studies); partial elemental diet during treatment followed by gradual low-fermentation diet reintroduction (low-FODMAP, specific carbohydrate diet, or SIBO-specific food guide); identifying and treating underlying hypothyroidism, MMC dysfunction (particularly post-infectious with vinculin/CdtB antibodies detected via IBS-Smart test); and reforming eating habits (no snacking between meals allows adequate MMC cycles—the most overlooked SIBO prevention measure).
Irritable Bowel Syndrome: Functional Root-Cause Assessment
Irritable Bowel Syndrome (IBS) affects approximately 10-15% of the global population—making it the most common functional gastrointestinal disorder and one of the most frequent reasons for gastroenterological consultation. The Rome IV criteria (Drossman 2016) define IBS as recurrent abdominal pain at least 1 day/week in the past 3 months, associated with two or more of: change in stool frequency, change in stool form/appearance, and pain related to defecation. IBS subtypes are defined by predominant bowel habit: IBS-C (constipation predominant), IBS-D (diarrhea predominant), IBS-M (mixed/alternating), and IBS-U (unclassified). Conventional management—antispasmodics, antidepressants, loperamide, rifaximin for IBS-D, linaclotide/lubiprostone for IBS-C—addresses symptoms without identifying underlying causes.
Functional gastroenterology approaches IBS as a syndrome with multiple possible biological causes that can be identified and specifically addressed. The most common SIBO-IBS overlap has been described above. Additional causes include: food sensitivities (particularly gluten—even without celiac disease, non-celiac gluten sensitivity [NCGS] causes IBS-like symptoms in 6% of the population; Volta 2012 systematic review); visceral hypersensitivity (lowered pain threshold in the gastrointestinal tract, mediated by sensitized TRPV1 and TRPA1 receptor upregulation—this is a CNS-mediated amplification of gut pain signals rather than structural gut pathology, responsive to low-dose TCAs, SSRIs, and gut-directed hypnotherapy); mast cell activation in the intestinal wall (mast cells degranulate inappropriately in response to food antigens, stress, and microbial patterns, releasing histamine, tryptase, and PGE2—creating visceral hypersensitivity and altered motility); post-infectious IBS from prior viral or bacterial gastroenteritis (10-15% of IBS cases are precipitated by documented gastrointestinal infections); and bile acid malabsorption (affecting 25-30% of IBS-D patients—excess bile acids reaching the colon cause secretory diarrhea, diagnosed by SeHCAT scan or 7α-hydroxy-4-cholesten-3-one [7αC4] measurement, treatable with bile acid sequestrants).
The low-FODMAP diet (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols—the short-chain carbohydrates fermented by colonic bacteria, producing gas and osmotic effects) is the most evidence-based dietary intervention for IBS. Developed at Monash University (Gibson 2010), the low-FODMAP diet restricts fructose (apples, pears, high-fructose corn syrup), lactose (dairy), fructans (wheat, garlic, onion, leeks), galacto-oligosaccharides (legumes), and polyols (sorbitol, mannitol, xylitol, stone fruits) during a 6-8 week elimination phase, followed by systematic reintroduction to identify individual trigger categories. The Staudacher 2011 AJCN RCT (n=41) found low-FODMAP diet superior to standard dietary advice for overall IBS symptom severity (68% vs. 23% symptom reduction). A subsequent Monash RCT (Halmos 2014, Gastroenterology, n=30 crossover) confirmed significant improvements in all IBS symptom parameters. Individual FODMAP tolerance testing during reintroduction avoids unnecessarily restrictive long-term exclusion of high-FODMAP foods that are prebiotic and beneficial for gut microbiome diversity—the low-FODMAP diet is not meant to be permanent.
Functional GERD and H. Pylori: Root-Cause Assessment
Gastroesophageal reflux disease (GERD)—affecting 20% of Western adults weekly—is conventionally managed with proton pump inhibitors (PPIs), which effectively suppress gastric acid secretion. While PPIs are highly effective for symptom relief, they create significant concerns in long-term use: increased risk of Clostridioides difficile infection (OR 1.7), small intestinal bacterial overgrowth (as described), magnesium deficiency (impairs active magnesium absorption requiring gastric acid), B12 malabsorption (gastric acid required for R-factor cleavage enabling B12-intrinsic factor binding), calcium malabsorption (calcium carbonate requires acid solubilization—risk of hip fracture increases 44% with long-term PPI use per Yang 2006 JAMA), gut microbiome dysbiosis, and potential rebound hypersecretion on discontinuation.
Functional gastroenterology evaluation of GERD begins with questioning the reflexive acid-suppression approach. Paradoxically, hypochlorhydria (insufficient gastric acid)—common with aging, H. pylori infection, stress, and nutritional deficiencies—can produce GERD-like symptoms via multiple mechanisms: inadequate acid impairs LES (lower esophageal sphincter) tone (gastric acid presence is a LES-tightening signal; low acid produces a relatively hypotonic LES prone to inappropriate relaxation); undigested food ferments in the stomach (producing gas that forces whatever acid is present past the LES); and bacterial overgrowth in the stomach (normally sterilized by acid) produces lactic acid and organic acids that irritate the esophageal mucosa. Betaine HCl challenge testing (administering betaine HCl with pepsin, increasing dose until warmth/burning is perceived—the dose at which burning begins estimates the degree of hypochlorhydria) provides a clinical approximation of gastric acid status without invasive gastric pH monitoring.
Helicobacter pylori (H. pylori)—a gram-negative bacterium infecting the gastric mucosa in approximately 44% of the global population and 35-40% of Americans—is the primary cause of peptic ulcer disease (present in 95% of duodenal ulcers and 70-85% of gastric ulcers), atrophic gastritis, and gastric adenocarcinoma (IARC Group 1 carcinogen for gastric cancer; H. pylori attributable for 78% of all non-cardia gastric cancers). H. pylori’s primary pathogenicity factor is CagA (cytotoxin-associated gene A protein), injected into gastric epithelial cells via Type IV secretion system—activating CagA-SHP2 oncogenic signaling, disrupting epithelial polarity, and driving IL-8 production that recruits neutrophils and promotes mucosal inflammation.
H. pylori diagnosis options: urea breath test (UBT—non-invasive, 95% sensitivity/specificity, the preferred non-endoscopic test), fecal H. pylori antigen test (ELISA-based, 94% sensitivity/specificity, affected by recent antibiotics or PPI use), H. pylori serology (IgG antibody—high sensitivity but cannot distinguish active from past infection, not recommended for diagnosis), and endoscopic biopsy with rapid urease test or histology (gold standard but invasive). Standard first-line eradication therapy: clarithromycin-based triple therapy (clarithromycin + amoxicillin + PPI × 14 days—but increasingly ineffective due to rising clarithromycin resistance, now above 20% in many regions); bismuth quadruple therapy (bismuth subcitrate + metronidazole + tetracycline + PPI × 14 days) is preferred in high clarithromycin-resistance regions or as second-line therapy; concomitant therapy and sequential therapy are alternatives with 90%+ eradication rates when properly administered. Post-eradication confirmation with UBT or fecal antigen (minimum 4 weeks after antibiotic completion, minimum 2 weeks off PPI) is essential—H. pylori eradication rates have declined to 75-80% with first-line triple therapy, making confirmation and second-line treatment critical.
Intestinal Permeability: The Leaky Gut Evidence Base
Intestinal permeability—colloquially termed “leaky gut”—refers to increased permeability of the intestinal epithelial barrier, allowing translocation of luminal contents (bacteria, bacterial toxins, partially digested food proteins) into the systemic circulation and triggering immune responses that can manifest locally (intestinal inflammation) or systemically (autoimmune disease, metabolic syndrome, neuroinflammation, skin conditions). The tight junction complex—including occludin, claudin-1/2/3, ZO-1/2/3, and tricellulin—maintains paracellular barrier integrity; these proteins are downregulated by pro-inflammatory cytokines (TNF-α, IFN-γ, IL-1β), zonulin (a physiologically-released mediator of tight junction disassembly triggered by gliadin and certain bacteria), alcohol, NSAIDs, and psychological stress (norepinephrine-mediated MLC kinase activation).
Clinical evidence for intestinal permeability as a disease driver has moved from theory to established mechanism in several conditions: type 1 diabetes (Watts 2019 demonstrated increased permeability precedes islet autoimmunity), celiac disease (gliadin-induced zonulin release creates transient permeability allowing gliadin peptide sampling by lamina propria dendritic cells—the initiating event in celiac autoimmunity), non-alcoholic fatty liver disease (LPS translocation from dysbiotic gut to portal circulation drives hepatic Kupffer cell activation—the “gut-liver axis”), and psychiatric conditions (blood-brain barrier disruption following intestinal permeability increases neuroinflammation). Fasano 2020 Nature Reviews Gastroenterology established the pathophysiological framework linking intestinal permeability to systemic disease—moving this from alternative medicine concept to mainstream gastroenterological consideration.
Testing intestinal permeability: the lactulose:mannitol (or lactulose:rhamnose) urine ratio test uses differential absorption of two sugars following oral administration—mannitol (small, 180 Da) is absorbed normally via transcellular transport, while lactulose (342 Da, large) is normally excluded. Elevated lactulose:mannitol ratio indicates paracellular permeability. Serum zonulin (though concerns about assay specificity exist—the Schramm 2020 paper establishing that many commercial assays detect complement proteins rather than actual zonulin), serum LPS-binding protein (LBP, which increases when LPS translocates—providing an indirect measure of bacterial endotoxin access to the systemic circulation), and Cyrex Array 2 (measuring IgA/IgM/IgG antibodies against LPS, occludin, claudin, and actomyosin—a multi-marker permeability panel with specificity for different anatomical compartments) provide complementary assessment.
Intestinal permeability restoration: L-glutamine (5-10 g/day)—the primary fuel for enterocytes, necessary for tight junction protein synthesis and cellular energy; zinc (25-40 mg/day)—essential for metalloenzyme activity in enterocyte maintenance and immunological function; colostrum (providing IGF-1, TGF-β, and secretory IgA—clinical trials show reduction in gut permeability and protection against NSAID-induced permeability); short-chain fatty acids, particularly butyrate (sodium butyrate 1-4 g/day or via high-fermentable-fiber diet)—the primary colonocyte fuel and HDAC inhibitor promoting tight junction expression; deglycyrrhizinated licorice (DGL, 760 mg before meals)—stimulates mucus production and IgA secretion; and bone broth (providing glycine, proline, and hydroxyproline—collagen precursors for tight junction protein synthesis). Avoidance of permeability drivers: NSAIDs (alternative analgesics where possible), alcohol reduction, gluten elimination in sensitive individuals, and aggressive stress management (cortisol/norepinephrine-mediated permeability effects).
Frequently Asked Questions
How do I know if I have SIBO, and what is the breath test?
SIBO symptoms include progressive bloating (worsening through the day, often severe by evening), abdominal discomfort, altered bowel habits (diarrhea in hydrogen-dominant, constipation in methane-dominant SIBO), burping, and sometimes nutritional deficiencies. A breath test at home or in a clinic measures hydrogen and methane gases after drinking a solution of lactulose or glucose—a positive hydrogen SIBO result is defined as a rise of 20 ppm above baseline within 90 minutes; a positive methane result is methane above 10 ppm at any time point. The IBS-Smart blood test (Gemelli BIOTECH) detects anti-vinculin and anti-CdtB antibodies—markers of post-infectious IBS with MMC dysfunction, indicating SIBO risk and guiding prokinetic therapy. Results should be interpreted in the clinical context of symptoms, as false positives (rapid transit) and false negatives (slow transit) can occur with lactulose testing specifically.
Is the low-FODMAP diet appropriate for everyone with IBS?
The low-FODMAP diet is appropriate as a diagnostic and therapeutic tool for most IBS patients, but should not be implemented as a permanent lifestyle. The elimination phase (6-8 weeks) is highly restrictive—excluding many high-fiber, prebiotic foods (garlic, onion, legumes, many fruits)—and has been shown to reduce gut microbiome diversity if maintained long-term. The critical second phase (systematic reintroduction of individual FODMAP categories over 8-12 weeks) is equally important: most patients tolerate some FODMAP categories but not others, and systematic reintroduction identifies specific triggers while restoring dietary variety and microbiome diversity. FODMAP-intolerant individuals who also have SIBO should treat the underlying SIBO before or alongside dietary modification—the SIBO-specific food guide (Dr. Siebecker) represents an integration of low-FODMAP and SIBO-appropriate dietary principles. Consultation with a dietitian specializing in low-FODMAP implementation improves outcomes and ensures nutritional adequacy during elimination.
Do I really need to treat H. pylori if it’s not causing symptoms?
Yes—current gastroenterological consensus (Maastricht VI/Florence Consensus, 2022) supports “test and treat” for H. pylori in virtually all individuals testing positive, regardless of whether peptic ulcer disease is present. Reasons: H. pylori is a Group 1 carcinogen with a clear causal role in gastric cancer—the most common stomach cancer etiology; eradication reduces gastric cancer risk by 50% (Sugano 2015 data); H. pylori infection is associated with iron deficiency anemia (competing for dietary iron), vitamin B12 deficiency, functional dyspepsia, and potentially cardiovascular disease via molecular mimicry mechanisms; and re-infection rates in developed countries are low (<1%/year), making successful eradication a one-time intervention with lifelong cancer prevention benefits. The exception for not treating is elderly patients with multiple antibiotic intolerances and short life expectancy where the risk-benefit ratio changes.
What causes “leaky gut” and how can I test for it?
Intestinal permeability (“leaky gut”) is driven by: NSAIDs (inhibit prostaglandin-mediated tight junction maintenance—even short-term NSAID use creates measurable permeability); alcohol (directly dissolves lipid-bilayer tight junction scaffolding); gluten/gliadin (triggers zonulin release from intestinal cells—a physiological permeability mediator); psychological stress (cortisol and norepinephrine activate MLC kinase, disrupting tight junction structure); gut dysbiosis (specifically zonulin-inducing bacteria and LPS from gram-negative bacteria); and extreme physical exertion (GI ischemia during intense exercise). Testing options include the lactulose:mannitol urine ratio test (functional permeability assessment), serum LPS-binding protein (LBP, measuring endotoxin translocation), and Cyrex Array 2 (measuring antibodies against tight junction proteins including occludin, claudin, and actomyosin). Restoration focuses on L-glutamine (5-10 g/day), zinc, butyrate, colostrum, and eliminating permeability triggers.
The gastrointestinal tract is far more than a digestive organ—it is the primary interface between the external world and the internal biological environment, housing 70% of the immune system, producing 95% of body serotonin, and maintaining the microbiome ecosystem that modulates metabolism, immunity, and neurological function across every organ system. When gut function is compromised—by SIBO, dysbiosis, intestinal permeability, H. pylori infection, or chronic low-grade inflammation—the consequences ripple throughout the body, manifesting as fatigue, autoimmune flares, depression, skin conditions, hormonal imbalance, and metabolic dysfunction that are often never connected to their gut origin by conventional medical evaluation. At The Private Practice, Dr. Biernacki integrates comprehensive functional gastroenterology assessment—SIBO breath testing, H. pylori evaluation, intestinal permeability testing, food sensitivity assessment, and comprehensive microbiome analysis—with targeted treatment protocols addressing the root causes of gut dysfunction. To schedule a functional gastroenterology consultation, call (810) 206-1402.